Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Genprex announced that its research collaborators at Meharry Medical College will present positive preclinical data on Reqorsa® Gene Therapy at the 39th Annual Society for Immunotherapy of Cancer Meeting in Houston, Texas, from November 6-10, 2024. The poster presentation will focus on Reqorsa's ability to modulate in vivo immune responses against cancers.
The study evaluates TUSC2's role in modulating immune responses in cancer. TUSC2 is the tumor suppressor gene used in REQORSA, which consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing uptake by normal tissue.
Ryan Confer, President and CEO of Genprex, expressed enthusiasm about the growing preclinical evidence supporting REQORSA's potential in treating various cancers and the opportunity to present these findings at the prestigious cancer meeting.
Genprex ha annunciato che i suoi collaboratori di ricerca al Meharry Medical College presenteranno dati preclinici positivi sulla terapia genica Reqorsa® al 39° Congresso Annuale della Società per l'Immunoterapia del Cancro a Houston, Texas, dal 6 al 10 novembre 2024. La presentazione del poster si concentrerà sulla capacità di Reqorsa di modulare le risposte immunitarie in vivo contro i tumori.
Lo studio valuta il ruolo di TUSC2 nella modulazione delle risposte immunitarie nel cancro. TUSC2 è il gene soppressore tumorale utilizzato in REQORSA, che consiste in un plasmide che esprime il gene TUSC2 racchiuso in nanoparticelle lipidiche non virali. REQORSA è progettato per portare il gene TUSC2 funzionante alle cellule tumorali minimizzando l'assorbimento da parte dei tessuti normali.
Ryan Confer, Presidente e CEO di Genprex, ha espresso entusiasmo riguardo alle crescenti evidenze precliniche che supportano il potenziale di REQORSA nel trattamento di vari tumori e all'opportunità di presentare questi risultati al prestigioso congresso sul cancro.
Genprex anunció que sus colaboradores de investigación en el Meharry Medical College presentarán datos preclínicos positivos sobre la terapia génica Reqorsa® en el 39º Congreso Anual de la Sociedad para la Inmunoterapia del Cáncer en Houston, Texas, del 6 al 10 de noviembre de 2024. La presentación del póster se centrará en la capacidad de Reqorsa de modular las respuestas inmunitarias in vivo contra los cánceres.
El estudio evalúa el papel de TUSC2 en la modulación de las respuestas inmunitarias en el cáncer. TUSC2 es el gen supresor tumoral utilizado en REQORSA, que consiste en un plásmido que expresa el gen TUSC2 encapsulado en nanopartículas lipídicas no virales. REQORSA está diseñado para entregar el gen TUSC2 funcional a las células cancerosas mientras minimiza la captación por tejidos normales.
Ryan Confer, Presidente y CEO de Genprex, expresó su entusiasmo por la creciente evidencia preclínica que apoya el potencial de REQORSA en el tratamiento de varios cánceres y la oportunidad de presentar estos hallazgos en el prestigioso congreso de cáncer.
Genprex는 Meharry Medical College의 연구 협력자들이 2024년 11월 6일부터 10일까지 텍사스 휴스턴에서 열리는 제39회 암 면역요법 학회에서 Reqorsa® 유전자 치료에 대한 긍정적인 전임상 데이터를 발표할 것이라고 발표했습니다. 포스터 발표는 Reqorsa가 암에 대한 생체 내 면역 반응을 조절하는 능력에 초점을 맞출 것입니다.
이 연구는 암에서 면역 반응을 조절하는 TUSC2의 역할을 평가합니다. TUSC2는 REQORSA에서 사용되는 종양 억제 유전자로, 이는 TUSC2 유전자가 발현되는 플라스미드가 비바이러스성 지질 기반 나노입자에 캡슐화되어 있는 것입니다. REQORSA는 작동하는 TUSC2 유전자를 암세포에 전달하도록 설계되었으며 정상 조직의 섭취를 최소화합니다.
Genprex의 사장 겸 CEO인 Ryan Confer는 REQORSA가 다양한 암을 치료하는 잠재력을 뒷받침하는 증가하는 전임상 증거에 대해 흥분하며, 이러한 발견을 권위 있는 암 학회에서 발표할 기회를 얻게 되어 기쁩니다.
Genprex a annoncé que ses collaborateurs de recherche au Meharry Medical College présenteront des données précliniques positives sur la thérapie génique Reqorsa® lors de la 39e Réunion Annuelle de la Société pour l'Immunothérapie du Cancer à Houston, Texas, du 6 au 10 novembre 2024. La présentation de l'affiche se concentrera sur la capacité de Reqorsa à moduler les réponses immunitaires in vivo contre les cancers.
L'étude évalue le rôle de TUSC2 dans la modulation des réponses immunitaires dans le cancer. TUSC2 est le gène suppresseur de tumeur utilisé dans REQORSA, qui consiste en un plasmide exprimant le gène TUSC2 encapsulé dans des nanoparticules lipidiques non virales. REQORSA est conçu pour fournir le gène TUSC2 fonctionnel aux cellules cancéreuses tout en minimisant l'absorption par les tissus normaux.
Ryan Confer, Président et CEO de Genprex, a exprimé son enthousiasme quant à l'accroissement des preuves précliniques soutenant le potentiel de REQORSA dans le traitement de divers cancers et à l'opportunité de présenter ces résultats lors de la prestigieuse réunion sur le cancer.
Genprex gab bekannt, dass die Forschungsmitarbeiter am Meharry Medical College positive präklinische Daten zur Reqorsa® Gentherapie auf dem 39. Jahreskongress der Gesellschaft für Immuntherapie von Krebs in Houston, Texas, vom 6. bis 10. November 2024 präsentieren werden. Die Posterpräsentation wird sich auf die Fähigkeit von Reqorsa konzentrieren, in vivo Immunantworten gegen Krebs zu modulieren.
Die Studie bewertet die Rolle von TUSC2 bei der Modulation von Immunantworten im Krebs. TUSC2 ist das Tumorsuppressorgen, das in REQORSA verwendet wird, welches aus einem Plasmid, das das TUSC2-Gen exprimiert, und nicht-viralen lipidhaltigen Nanopartikeln besteht. REQORSA ist so gestaltet, dass es das funktionierende TUSC2-Gen an Tumorzellen abgibt, während die Aufnahme durch normales Gewebe minimiert wird.
Ryan Confer, Präsident und CEO von Genprex, äußerte seine Begeisterung über die wachsenden präklinischen Beweise, die das Potenzial von REQORSA zur Behandlung verschiedener Krebsarten unterstützen, sowie über die Gelegenheit, diese Ergebnisse auf dem angesehenen Krebs-Kongress zu präsentieren.
- Positive preclinical data on Reqorsa® Gene Therapy to be presented at a prestigious cancer meeting
- REQORSA shows potential in modulating immune responses against cancers
- Growing body of preclinical evidence supporting REQORSA's potential in treating various cancers
- Laboratory studies show 10 to 33 times higher uptake of TUSC2 in tumor cells compared to normal cells
- None.
Insights
This preclinical data presentation on Reqorsa® Gene Therapy at a major cancer conference is moderately impactful for Genprex. The study focuses on TUSC2's role in modulating immune responses against cancers, which could potentially expand Reqorsa's applications. However, it's important to note that this is still preclinical data, not clinical trial results.
Key points to consider:
- The presentation at a prestigious cancer meeting may increase visibility and credibility for Genprex's research.
- Positive preclinical data on immune modulation could support future clinical trials and potential partnerships.
- The specificity of REQORSA in targeting cancer cells (10-33 times higher uptake than normal cells) is promising for its potential efficacy and safety profile.
- As a small-cap company (
$880,106 market cap), positive research developments can have a significant impact on investor sentiment.
While this news is encouraging for Genprex's research progress, investors should remain cautious as preclinical results don't always translate to clinical success. The company's financial position and timeline for clinical development will be important factors to monitor moving forward.
Poster Presentation to Focus on Reqorsa's Ability to Modulate In Vivo Immune Responses Against Cancers
"The body of preclinical evidence supporting REQORSA's potential in the treatment of a variety of cancers continues to grow as we bolster our robust research program for REQORSA with our collaborators at many academic institutions," said Ryan Confer, President and Chief Executive Officer at Genprex. "We are very pleased that our academic partners have been selected to present their findings on REQORSA at this prestigious cancer meeting, and we look forward to this presentation next month sharing more about TUSC2's role in modulating immune responses in cancer."
The featured Genprex-supported poster to be presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting:
Title: "TUSC2 Modulates Cancer Immune Responses"
Collaborator: Meharry Medical College
TUSC2 is the tumor suppressor gene used in REQORSA. REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-reqorsa-gene-therapy-at-the-society-for-immunotherapy-of-cancer-2024-annual-meeting-302268681.html
SOURCE Genprex, Inc.
FAQ
What is the focus of Genprex's (GNPX) poster presentation at the 2024 Society for Immunotherapy of Cancer Meeting?
When and where will Genprex's (GNPX) research collaborators present their findings on Reqorsa?
What is REQORSA and how does it work according to Genprex's (GNPX) research?
What were the results of laboratory studies on REQORSA's uptake in tumor cells for Genprex (GNPX)?
